OncoArendi Therapeutics SA (MOC) Stock Statistics & Valuation Metrics
Total Valuation
OncoArendi Therapeutics SA has a market cap or net worth of PLN 142.90M. The enterprise value is PLN 108.64M.
- Market Cap
- PLN 142.90M
- Enterprise Value
- PLN 108.64M
Share Statistics
OncoArendi Therapeutics SA has 24,723,785 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 24,723,785
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
OncoArendi Therapeutics SA’s return on equity (ROE) is -0.18 and return on invested capital (ROIC) is -23.73%.
- Return on Equity (ROE)
- -0.18
- Return on Assets (ROA)
- -0.17
- Return on Invested Capital (ROIC)
- -23.73%
- Return on Capital Employed (ROCE)
- -0.24
- Revenue Per Employee
- 0
- Profits Per Employee
- -153.81K
- Employee Count
- 102
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of OncoArendi Therapeutics SA is -11.57. OncoArendi Therapeutics SA’s PEG ratio is -0.12.
- PE Ratio
- -11.57
- PS Ratio
- 849.20
- PB Ratio
- 1.45
- Price to FCF
- -29.71
- Price to Operating Cash Flow
- -10.71
- PEG Ratio
- -0.12
Income Statement
In the last 12 months, OncoArendi Therapeutics SA had revenue of 0 and earned -15.69M in profits. Earnings per share was -0.77.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -22.04M
- Pretax Income
- -15.69M
- Net Income
- -15.69M
- EBITDA
- -19.03M
- Earnings Per Share (EPS)
- -0.77
Cash Flow
In the last 12 months, operating cash flow was -13.34M and capital expenditures 8.53M, giving a free cash flow of -4.81M billion.
- Operating Cash Flow
- -13.34M
- Free Cash Flow
- -4.81M
- Free Cash Flow per Share
- -0.19
Dividends & Yields
OncoArendi Therapeutics SA pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -3.37%
- Earnings Yield
- -7.64%
Stock Price Statistics
- Beta
- 0.35
- 52-Week Price Change
- -13.86%
- 50-Day Moving Average
- 6.64
- 200-Day Moving Average
- 6.23
- Relative Strength Index (RSI)
- 35.29
- Average Volume (3m)
- 50.81K
Important Dates
OncoArendi Therapeutics SA upcoming earnings date is Apr 06, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Oct 30, 2026
- Next Earnings Date
- Apr 06, 2027
- Ex-Dividend Date
- ―
Financial Position
OncoArendi Therapeutics SA as a current ratio of 4.79, with Debt / Equity ratio of 6.05%
- Current Ratio
- 4.79
- Quick Ratio
- 4.79
- Debt to Market Cap
- 0.02
- Net Debt to EBITDA
- 0.58
- Interest Coverage Ratio
- -286.48
Taxes
In the past 12 months, OncoArendi Therapeutics SA has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
OncoArendi Therapeutics SA EV to EBITDA ratio is -10.17, with an EV/FCF ratio of -27.98.
- EV to Sales
- 799.54
- EV to EBITDA
- -10.17
- EV to Free Cash Flow
- -27.98
- EV to Operating Cash Flow
- -10.08
Balance Sheet
OncoArendi Therapeutics SA has PLN 12.03M in cash and marketable securities with PLN 3.67M in debt, giving a net cash position of PLN 8.36M billion.
- Cash & Marketable Securities
- PLN 12.03M
- Total Debt
- PLN 3.67M
- Net Cash
- PLN 8.36M
- Net Cash Per Share
- PLN 0.34
- Tangible Book Value Per Share
- PLN 0.45
Margins
Gross margin is -3893.23%, with operating margin of -9330.73%, and net profit margin of -6489.85%.
- Gross Margin
- -3893.23%
- Operating Margin
- -9330.73%
- Pretax Margin
- -6489.85%
- Net Profit Margin
- -6489.85%
- EBITDA Margin
- -7865.24%
- EBIT Margin
- -9330.73%
Analyst Forecast
The average price target for OncoArendi Therapeutics SA is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- 0
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- 58.91%
